All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
World-leading experts in MDS shared the top abstracts from the 62nd American Society Hematology (ASH) Annual Meeting and Exposition that they believed could have the greatest impact on clinical practice.
ASH 2020 | Practice-changing abstracts in myelodysplastic syndromes
Did you miss ASH 2020? Download the resource below to view our Steering Committee's selection of practice-changing abstracts in MDS.Download Here
Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical...
Results from the phase II P-2001 study on pevonedistat plus azacytidine for high-risk MDS
To further explore the clinical efficacy and safety of pevo in patients with high-risk MDS, CMML, or low-blast AML, Mikkael Sekeres and colleagues designed the...
Subscribe to get the best content related to MDS delivered to your inbox